There have been many dispensing innovations in recent years, particularly in the consumer goods space, so we may have passed the peak of the current replacement cycle.Some pharmaceutical companies have taken drug delivery development in-house. If that trend intensifies, it could result in lower
After reviewing AptarGroup 's second-quarter results, we are maintaining our $70 per share fair value estimate and our narrow economic moat rating
AptarGroup ( ATR -1% ) Q2 results : Total Revenues: $670.6M (+4.6%), Beauty + Home: $385.2M (+2.7%), Pharma: $195
AptarGroup (NYSE: ATR ): Q2 EPS of $0.79 misses by $0.03 . Revenue of $670.63M (+4.6% Y/Y) misses by $13.31M . Press Release Post your comment!
AptarGroup Inc. (NYSE: ATR ) declares $0.28/share quarterly dividend , in line with previous. Forward yield 1.72% Payable Aug. 20; for shareholders of record July 30; ex-div July 28. Post your comment!
After reviewing AptarGroup 's first-quarter report, we're increasing our fair value estimate to $70 per share from $66, due primarily to an improved
After reviewing AptarGroup 's first-quarter report, we expect to slightly increase our fair value estimate of $66 per share due primarily to an improved
After reviewing AptarGroup 's fourth-quarter and full-year results, we are increasing our fair value estimate to $66 per share from $60 per share
AptarGroup ATR might be a lesser-known name in the packaging industry, but it's one to get to know. Its dispensing niche has proved
After reviewing AptarGroup 's third-quarter results, we are increasing our fair value estimate to $60 per share from $58 per share due to a slightly